吡格列酮是噻唑烷二酮类抗糖尿病药物,属胰岛素增敏剂,作用机制与胰岛素的存在有关,可减少外周组织和肝脏的胰岛素抵抗,增加依赖胰岛素的葡萄糖的处理,并减少肝糖的输出。
匹格列酮 | Pioglitazone | 111025-46-8 |
匹格列酮杂质A | 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-5-hydroxy-2,4-thiazolidinedione | 625853-74-9 |
匹格列酮杂质B | 5-{4-[2-(5-Ethyl-2-pyridinyl) ethoxy] benzylidene}-2,4-thiazolidinedione | 144809-28-9 |
匹格列酮杂质C | 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-N-[2-(5-ethylpyridin-2-yl)ethyl]-2,4-thiazolidinedione | 952188-00-0 |
匹格列酮杂质D | Ethyl (2RS)-2-(carbamoylsulphanyl)-3-[4-[2-(5-ethylpyridin-2-yl) ethoxy] | 868754-41-0 |
匹格列酮杂质E | Ethyl 3-[4-[2-(5-ethylpyridin-2-yl) ethoxy] phenyl] propanoate | 868754-42-1 |
匹格列酮杂质 | Pioglitazone Fluoro Impurity | 291536-42-0 |
匹格列酮杂质 | Pioglitazone Imino Impurity | 105355-26-8 |
匹格列酮杂质 | Pioglitazone N-Oxide | 145350-09-0 |
匹格列酮杂质 | Pioglitazone Sulfonic Acid | 625853-73-8 |
匹格列酮杂质 | Pioglitazone Bromo Impurity |
|
匹格列酮杂质 | Pioglitazone Metabolite M1 |
|
匹格列酮杂质 | Pioglitazone Metabolite M2 |
|
匹格列酮杂质 | Pioglitazone Metabolite M3 |
|
匹格列酮杂质 | Pioglitazone Metabolite M4 |
|
匹格列酮杂质 | Pioglitazone Metabolite M5 |
|
深圳远扬化学可提供吡格列酮申报所用全套杂质, 随货附CoA证书,HNMR,MS,HPLC图谱,纯度符合申报要求,欢迎我司。请点击本页标题下方“进入该公司展台” 查看我司信息。